Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky

In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Joined by esteemed oncologists Dr. Sara Tolaney from Dana-Farber Cancer Institute and Dr. Adam Brufsky from UPMC Hillman Cancer Center, the discussion focused on real-world scenarios involving adjuvant and metastatic settings. Key topics included: The recent updates from the MonarchE and NATALEE trials, highlighting the approval of abemaciclib and ribociclib. Strategies for selecting the right adjuvant treatment for high-risk patients, including dosing considerations and side effect management. Insights into managing common toxicities associated with CDK4/6 inhibitors, such as diarrhea and QTc prolongation. The role of CDK4/6 inhibitors in patients with visceral involvement and the implications of using these therapies in the metastatic setting. Whether you're a healthcare professional or someone interested in the latest advancements in breast cancer treatment, this episode provided valuable insights and expert opinions on navigating complex treatment decisions. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Don't forget to subscribe for more episodes and send us your challenging cases for future discussions! #CDK4/6i #BreastCancer #MonarchE #NATALEE #Abemaciclib #Ribociclib #OncologyBrothers #HRpositive